Lebrikizumab improved hand and foot atopic dermatitis in a Phase 3b trial, according to results reported by Patient Care Online. The finding matters because hand and foot disease resists many standard therapies and drives a disproportionate share of the functional burden in atopic dermatitis.

The trial evaluated lebrikizumab, an interleukin-13 inhibitor, in patients whose atopic dermatitis involved the hands and feet. Phase 3b data now indicate improvement in this population, extending the clinical profile of the drug beyond what earlier pivotal programs established for moderate-to-severe atopic dermatitis at large.

Hand and foot involvement occupies a distinct place in the atopic dermatitis treatment conversation. Palmar and plantar skin is thick, fissuring is common, and pain on gripping, walking and performing daily tasks frequently outranks itch as the complaint patients raise first. Standard potency topical corticosteroids and calcineurin inhibitors often underperform at these sites, and systemic options have historically been studied in mixed populations in which hand and foot disease was not analyzed separately. A dedicated Phase 3b readout in this subgroup therefore gives clinicians trial-based evidence where they previously relied on inference.

Lebrikizumab targets IL-13, a cytokine central to the type 2 inflammatory cascade that drives atopic dermatitis. By blocking the IL-13 pathway, the drug addresses the same signaling axis as dupilumab's dual IL-4/IL-13 inhibition, but through a more selective mechanism. Earlier Phase 3 programs supported lebrikizumab's efficacy and tolerability in moderate-to-severe atopic dermatitis; the new Phase 3b data point to benefit in the anatomically specific, harder-to-treat hand and foot phenotype.

For dermatologists, the practical question is what the result means at the point of care. Patients with dominant hand and foot disease often fail to reach clearance on first-line therapy and progress to systemic treatment. Clinicians selecting among biologics now have Phase 3b evidence indicating that lebrikizumab improves disease at these sites, which may inform shared decision-making for patients whose occupation or daily function depends on hand use — healthcare workers, mechanics, food handlers and others whose skin barrier is under constant mechanical stress.

The result also reflects a broader shift in atopic dermatitis trial design. Regulators and clinical investigators increasingly recognize that average scores across a large population can obscure outcomes in localized but functionally devastating disease. Analyses focused on the hands and feet, along with other regional assessments, give a sharper picture of whether a therapy works where the burden is concentrated.

Clinicians will want to see the full dataset as it moves through publication and presentation, including the specific endpoints used to measure hand and foot response, effect sizes, durability of improvement over the maintenance period and safety findings in this cohort. How lebrikizumab's hand and foot results compare head-to-head with other systemic agents remains an open question, and broader adoption in this phenotype will depend on how the data are integrated into treatment guidelines and coverage decisions.